The Momentum trial from Sarepta Therapeutics is investigating SRP-5051 (vesleteplirsen) for use among male patients aged 8 to 21 years who have Duchenne muscular dystrophy amenable to exon 51 skipping.
Positive phase 2 data on SRP-5051 (vesleteplirsen; Sarepta Therapeutics) for use among ambulatory and nonambulatory male patients who have Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping show the treatment’s effectiveness at its lower and higher determined doses, according to a press release from Sarepta Therapeutics.1
Efficacy of the next-generation peptide phosphorodiamidate morpholino oligomer is currently being investigated in part B of the global, multi-ascending-dose Momentum trial.2 Part A evaluated SRP-5051 to determine its maximum tolerated dose, with the low and high doses being approximately 20 mg/kg and 30 mg/kg, both administered every 4 weeks.
To qualify for trial enrollment, patients had to be male, aged 7 to 21 years, and treatment naïve; have a genetic diagnosis of DMD amenable to exon 51 skipping treatment; have a 12-week history of continuous stable corticosteroid dosing or not have received any corticosteroids for at least 12 weeks prior to SRP-5051 administration; not have received any exon-51 skipping treatment in the 4 weeks leading up to their Momentum screening or any gene therapy for DMD; and not have a diagnosis of hypomagnesemia, serum creatinine above the upper limit of normal, or abnormal electrolyte values at screening.3
For those in the 30 mg/kg dose cohort (n = 20), SRP-5051 produced these results:
For those in the 20 mg/kg dose cohort (n = 20), SRP-5051 produced these results:
Compared with a weekly 30 mg/kg dose of eteplirsen at 24 weeks, the positive changes in dystrophin expression and exon skipping seen with the 30 mg/kg dose of SRP-5051 symbolize 12.2- and 24.6-fold increases, respectively, and the improvements at the 20-mg/kg dose, 4.3- and 4.9-fold increases.
“The dystrophin production delivered by SRP-5051 in the Momentum study is very encouraging. Importantly, with effective supplementation and monitoring, we have not seen additional complications from the hypomagnesemia,” said Eugenio Mercuri, MD, PhD, head of the Neuromuscular Unit, Catholic University, Rome, Italy, and an investigator in the study, in the statement from Sarepta. “The results with SRP-5051 to date suggest it could play an important role in the treatment of Duchenne patients with a confirmed exon 51 amenable mutation.”
Hypomagnesemia, or magnesium deficiency, is 1 of 2 serious treatment-emergent adverse events seen in part B of the Momentum trial; there were 4 cases in addition to the 3 instances of hypokalemia, or lower-than-normal potassium in the blood.
Overall, these newest data from Momentum part b support a favorable benefit-risk profile for SRP-5051.
SRP-5051 is also currently being investigated in an open-label extension study.4
References
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More